Rayan Kaedbey

572 total citations
26 papers, 192 citations indexed

About

Rayan Kaedbey is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Rayan Kaedbey has authored 26 papers receiving a total of 192 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 13 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Rayan Kaedbey's work include Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (8 papers) and Peptidase Inhibition and Analysis (6 papers). Rayan Kaedbey is often cited by papers focused on Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (8 papers) and Peptidase Inhibition and Analysis (6 papers). Rayan Kaedbey collaborates with scholars based in Canada, United States and Spain. Rayan Kaedbey's co-authors include Suzanne Trudel, Esther Masih‐Khan, Mark Dowar, Jessica Liu, Olena Kis, Zhihua Li, Suzanne Kamel‐Reid, Trevor J. Pugh, Tiantian Li and Scott V. Bratman and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rayan Kaedbey

21 papers receiving 189 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rayan Kaedbey Canada 6 140 96 92 59 27 26 192
Eugenia Cordero Sweden 6 71 0.5× 131 1.4× 69 0.8× 38 0.6× 13 0.5× 9 211
Kylee Maclachlan United States 9 168 1.2× 268 2.8× 118 1.3× 38 0.6× 20 0.7× 43 343
Brandon Blue United States 6 79 0.6× 72 0.8× 68 0.7× 46 0.8× 12 0.4× 27 163
Αριστέα-Μαρία Παπανώτα Greece 11 96 0.7× 95 1.0× 57 0.6× 61 1.0× 29 1.1× 27 206
Mahesh Swaminathan United States 8 172 1.2× 111 1.2× 45 0.5× 26 0.4× 15 0.6× 31 239
Romanos Sklavenitis‐Pistofidis United States 8 145 1.0× 156 1.6× 127 1.4× 39 0.7× 19 0.7× 28 297
Adam del Corral United States 4 219 1.6× 138 1.4× 82 0.9× 35 0.6× 12 0.4× 5 332
Kota Fukumoto Japan 9 103 0.7× 81 0.8× 73 0.8× 24 0.4× 62 2.3× 20 195
Christine Greil Germany 9 181 1.3× 176 1.8× 130 1.4× 28 0.5× 17 0.6× 24 295
T. Peretz Israel 4 78 0.6× 122 1.3× 67 0.7× 76 1.3× 66 2.4× 8 223

Countries citing papers authored by Rayan Kaedbey

Since Specialization
Citations

This map shows the geographic impact of Rayan Kaedbey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rayan Kaedbey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rayan Kaedbey more than expected).

Fields of papers citing papers by Rayan Kaedbey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rayan Kaedbey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rayan Kaedbey. The network helps show where Rayan Kaedbey may publish in the future.

Co-authorship network of co-authors of Rayan Kaedbey

This figure shows the co-authorship network connecting the top 25 collaborators of Rayan Kaedbey. A scholar is included among the top collaborators of Rayan Kaedbey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rayan Kaedbey. Rayan Kaedbey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mian, Hira, Alissa Visram, Suzanne Trudel, et al.. (2025). Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada. Clinical Lymphoma Myeloma & Leukemia. 25(6). e404–e410.
2.
McCurdy, Arleigh, Donna Reece, Michael P. Chu, et al.. (2025). Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis. Clinical Lymphoma Myeloma & Leukemia. 25(7). e491–e500.e1.
3.
Kaedbey, Rayan, et al.. (2025). Preliminary results of 3D telomeres profiling for myeloma MRD and evaluation of concordance between blood and marrow.. Journal of Clinical Oncology. 43(16_suppl).
4.
Leclair, Valérie, et al.. (2025). Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report. SAGE Open Medical Case Reports. 13. 2050313X251336022–2050313X251336022. 1 indexed citations
5.
Leblanc, Richard, Jean Roy, Julie Anne Côté, et al.. (2024). Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia. Cancer Medicine. 13(17). e70192–e70192. 1 indexed citations
6.
Lancman, Guido, Kevin Song, Darrell White, et al.. (2024). Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement. Frontiers in Oncology. 14. 1446995–1446995. 2 indexed citations
7.
8.
9.
McCurdy, Arleigh, Donna Reece, Christopher P. Venner, et al.. (2023). Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 142(Supplement 1). 3364–3364. 1 indexed citations
10.
LeBlanc, Richard, Jean Roy, Marc Lalancette, et al.. (2023). Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments. Blood. 142(Supplement 1). 3399–3399. 1 indexed citations
11.
McCurdy, Arleigh, Hsien Seow, Gregory R. Pond, et al.. (2023). Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 108(12). 3384–3391. 13 indexed citations
12.
Cerquozzi, Sonia, Harold J. Olney, Anargyros Xenocostas, et al.. (2023). Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leukemia Research. 133. 107374–107374. 6 indexed citations
13.
McCurdy, Arleigh, Hira Mian, Richard LeBlanc, et al.. (2023). Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer Journal. 13(1). 111–111. 10 indexed citations
14.
LeBlanc, Richard, Hira Mian, Donna Reece, et al.. (2023). Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal Of Haematology. 111(5). 815–823. 1 indexed citations
15.
Mateos, María‐Victoria, Nizar J. Bahlis, Andrew Spencer, et al.. (2023). P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB. HemaSphere. 7(S3). e75458a8–e75458a8. 4 indexed citations
16.
Kaedbey, Rayan, Christopher P. Venner, Arleigh McCurdy, et al.. (2022). P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomidecontaining regimens in the real world: a report from the Canadian Myeloma Research Group Database. Clinical Lymphoma Myeloma & Leukemia. 22. S145–S146. 1 indexed citations
17.
LeBlanc, Richard, Christopher P. Venner, Esther Masih‐Khan, et al.. (2022). Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database. Blood. 140(Supplement 1). 7192–7194. 1 indexed citations
18.
19.
Kis, Olena, Rayan Kaedbey, Signy Chow, et al.. (2017). Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nature Communications. 8(1). 15086–15086. 100 indexed citations
20.
Kis, Olena, Signy Chow, Rayan Kaedbey, et al.. (2017). Targeted Sequencing of Circulating Cell-free DNA in Multiple Myeloma Allows Analysis of Somatic Mutations, Copy Number Aberrations, and Translocations. Clinical Lymphoma Myeloma & Leukemia. 17(1). e93–e94. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eugenia Cordero Breakdown of academic impact, for papers by Kylee Maclachlan Breakdown of academic impact, for papers by Brandon Blue Breakdown of academic impact, for papers by Αριστέα-Μαρία Παπανώτα Breakdown of academic impact, for papers by Mahesh Swaminathan Breakdown of academic impact, for papers by Romanos Sklavenitis‐Pistofidis Breakdown of academic impact, for papers by Adam del Corral Breakdown of academic impact, for papers by Kota Fukumoto Breakdown of academic impact, for papers by Christine Greil Breakdown of academic impact, for papers by T. Peretz
Rankless by CCL
2026